Table 1.
Characteristics of patients with sensitive EGFR mutations receiving ICIs.
| Characteristic | All patients (N = 99) |
|---|---|
| Median age (range), y | 59(34-92) |
| Gender, n (%) | |
| Male | 44 (44.44) |
| Female | 55 (55.56) |
| ECOG score, n (%) | |
| 0-1 | 70 (70.71) |
| ≥2 | 29 (29.29) |
| Smoking history, n (%) | |
| Current or former | 22 (22.22) |
| Never | 77 (77.78) |
| Pathologic type, n (%) | |
| Adenocarcinoma | 90 (90.91) |
| Squamous cell carcinoma | 3 (3.03) |
| Mixed type | 6 (6.06) |
| TNM stage, n (%) | |
| IIIc | 3 (3.03) |
| IV | 96 (96.97) |
| Sites of metastasis | |
| Brain | 41 (41.41) |
| Liver | 21 (21.21) |
| Bone | 54 (54.55) |
| Primary EGFR mutation | |
| 19del | 50 (50.51) |
| L858R | 42 (42.42) |
| others | 7 (7.07) |
| Secondary T790M mutation | |
| Yes | 28 (28.28) |
| No | 37 (37.37) |
| Unknown | 34 (34.34) |
| Previous EGFR-TKI treatment | |
| 1st/2nd generation TKI | 44 (44.44) |
| 1st/2nd ➝3rd generation TKI | 48 (48.48) |
| 3rd generation TKI | 7 (7.07) |
| Prior lines of therapy, n (%) | |
| ≤2 | 43 (43.43) |
| >2 | 56 (56.57) |
| ICIs | |
| Anti-PD-1 antibody | 93 (93.94) |
| Anti-PD-L1 antibody | 6 (6.06) |
| Treatment | |
| Monotherapy | 20 (20.20) |
| Combination therapy | |
| I+C | 27 (27.27) |
| I+A | 19 (19.19) |
| I+A+C | 28 (28.28) |
| PD-1 inhibitor + CTLA-4 inhibitor | 1 (1.01) |
| PD-1 inhibitor + EGFR-TKI | 4 (4.04) |
ECOG, Eastern Cooperative Oncology Group; EGFR, epidermal growth factor receptor; 19del, exon 19 deletion; ICI, immune checkpoint inhibitor; PD-1, programmed death 1; PD-L1, programmed cell death-ligand 1; I + C, Immunotherapy-chemotherapy combination treatment; I + A, Immunotherapy-antiangiogenic combination treatment; I + A + C, Immunotherapy-antiangiogenic-chemotherapy combination treatment; CTLA-4, cytotoxic T-cell lymphocyte-4; TKI, tyrosine kinase inhibitor.